USA - NASDAQ:INMD - IL0011595993 - Common Stock
The current stock price of INMD is 14.6 USD. In the past month the price decreased by -4.58%. In the past year, price decreased by -18.93%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.23 | 219.11B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.92 | 206.56B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.21 | 149.52B | ||
| SYK | STRYKER CORP | 26.96 | 135.73B | ||
| IDXX | IDEXX LABORATORIES INC | 56.27 | 56.77B | ||
| BDX | BECTON DICKINSON AND CO | 12.6 | 52.06B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.72 | 49.36B | ||
| RMD | RESMED INC | 25.26 | 36.50B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.01 | 33.55B | ||
| PODD | INSULET CORP | 70.1 | 22.55B | ||
| DXCM | DEXCOM INC | 29.48 | 21.51B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.97 | 17.58B |
InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The firm have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
INMODE LTD
Tavor Building, Sha'ar Yokneam, Pob 533
Yokneam 2069200 IL
CEO: Moshe Mizrahy
Employees: 599
Phone: 97249097470
InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The firm have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
The current stock price of INMD is 14.6 USD. The price increased by 1.04% in the last trading session.
INMD does not pay a dividend.
INMD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
13 analysts have analysed INMD and the average price target is 16.98 USD. This implies a price increase of 16.32% is expected in the next year compared to the current price of 14.6.
INMODE LTD (INMD) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
INMODE LTD (INMD) will report earnings on 2026-02-02, before the market open.
ChartMill assigns a fundamental rating of 7 / 10 to INMD. INMD scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
Over the last trailing twelve months INMD reported a non-GAAP Earnings per Share(EPS) of 1.58. The EPS decreased by -23.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 44.5% | ||
| ROA | 25.23% | ||
| ROE | 28.44% | ||
| Debt/Equity | 0 |
13 analysts have analysed INMD and the average price target is 16.98 USD. This implies a price increase of 16.32% is expected in the next year compared to the current price of 14.6.
For the next year, analysts expect an EPS growth of -9.5% and a revenue growth -8.12% for INMD